Adalimumab Market
Adalimumab Market Size, Share & Trends Analysis Report, By Product Type (Original/Breference Adalimumab, Biosimilar Adalimumab), By Treatment Stage (First-line Biologic Therapy, Second-line Biologic Therapy, Maintenance Therapy), By End User (Hospitals, Specialty Clinics, Ambulatory Infusion Centers, Homecare Settings), Forecast Period (2026-2035)
Adalimumab market was valued at $10.8 billion in 2025 and is projected to reach $21.5 billion by 2035, expanding at a CAGR of 7.1% during the forecast period from 2026 to 2035. Increasing prevalence of autoimmune diseases, growing biosimilar penetration, and rising biologic drug accessibility are key factors supporting market growth worldwide. Adalimumab is one of the most widely prescribed TNF-alpha inhibitor biologics for chronic inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, ankylosing spondylitis, and hidradenitis suppurativa. According to the World Health Organization (WHO), approximately 18 million people globally were living with rheumatoid arthritis in 2019, highlighting the increasing burden of autoimmune disorders requiring long-term biologic therapies. Additionally, the U.S. Food and Drug Administration (FDA) continues to accelerate biosimilar approvals to improve affordability and treatment accessibility for inflammatory diseases.
Hospitals and specialty clinics remain major end-use settings due to increasing biologic treatment adoption and reimbursement support. Growing demand for self-administered biologics and home care therapies is further contributing to market expansion. The rise of interchangeable biosimilars and payer-driven cost reduction strategies is expected to significantly reshape the competitive landscape over the next decade.
Market Dynamics
Rising Autoimmune Disease Burden and Biosimilar Adoption Driving Market Growth
The increasing incidence of autoimmune and chronic inflammatory disorders is one of the major growth drivers for the global adalimumab market. According to the WHO, rheumatoid arthritis affects around 18 million people globally, with women accounting for nearly 70% of cases. Inflammatory bowel diseases and psoriasis prevalence are also increasing globally due to aging populations, lifestyle changes, and improved disease diagnosis.
Government support for biosimilars is improving patient access to biologic therapies. The FDA reported continued growth in biosimilar approvals between 2023 and 2025 to promote affordability in the biologics market. Healthcare systems in the U.S., Europe, and Asia-Pacific are increasingly adopting biosimilar substitution policies to reduce treatment costs associated with chronic autoimmune disorders.
Manufacturers are expanding commercialization strategies through high-concentration citrate-free formulations, interchangeable biosimilars, and regional partnerships. In 2025, companies including AbbVie, Amgen, Samsung Bioepis, and Sandoz continued to strengthen biologics manufacturing and distribution capabilities to address rising patient demand and expand global market penetration.
Pricing Pressure and Regulatory Complexity Challenging Market Expansion
Despite strong growth potential, the adalimumab market faces considerable pricing pressure due to increasing biosimilar competition and reimbursement constraints. Following the expiration of key Humira patents across major regions, healthcare providers and insurers have aggressively shifted toward lower-cost biosimilar alternatives, resulting in significant price erosion for branded biologics.
Biologic manufacturing remains highly complex and capital-intensive due to stringent regulatory requirements, cold-chain logistics, and quality consistency standards. Regulatory approval processes for biosimilars require extensive analytical characterization and clinical comparability studies, increasing development timelines and commercialization costs.
Supply chain disruptions and manufacturing scalability challenges also continue to impact biologics production globally. Companies are responding through investments in manufacturing automation, regional production facilities, and strategic collaborations to strengthen supply reliability. Additionally, manufacturers are increasingly focusing on interchangeable biosimilars and patient-support programs to maintain market competitiveness amid intensifying pricing pressure.
Market Segmentation
Adalimumab Market Segmentation
- Based on the product type, the market is segmented into original/breference adalimumab and biosimilar adalimumab.
- Based on the treatment stage, the market is segmented into first-line biologic therapy, second-line biologic therapy, and maintenance therapy.
- Based on the end user, the market is segmented into hospitals, specialty clinics, ambulatory infusion centers, and home care settings.
Original/Breference Adalimumab Segment Leads the Market
The Original/Breference Adalimumab segment continues to dominate the global market due to strong physician familiarity, extensive clinical evidence, and broad regulatory approvals across multiple autoimmune indications. Humira, developed by AbbVie, has historically maintained significant market leadership supported by long-term reimbursement agreements and established patient trust.
Hospitals and specialty clinics continue to prescribe branded adalimumab therapies for severe inflammatory conditions requiring stable biologic treatment outcomes. Between 2022 and 2026, AbbVie implemented lifecycle management strategies, including expanded patient-support services and international commercialization initiatives, to sustain market competitiveness amid rising biosimilar penetration.
Additionally, reference biologics maintain strong demand in regions where biosimilar substitution policies are still evolving, particularly across developing healthcare markets.
Biosimilar Adalimumab Segment to Record Strong Growth
The Biosimilar Adalimumab segment is projected to witness the fastest growth during the forecast period due to increasing regulatory approvals, payer-driven cost optimization strategies, and expanding interchangeable biosimilar availability.
Technological advancements in biologics manufacturing and analytical comparability studies are supporting rapid biosimilar commercialization globally. Manufacturers, including Amgen, Samsung Bioepis, Celltrion, Sandoz, and Boehringer Ingelheim, are investing heavily in biosimilar pipeline expansion and regional distribution agreements.
The FDA’s support for interchangeable biosimilars and favorable reimbursement frameworks in Europe are accelerating physician confidence and patient adoption. Emerging markets across Asia-Pacific and Latin America are also creating substantial opportunities for lower-cost biologic therapies due to increasing healthcare access and growing autoimmune disease diagnosis rates.
Regional Outlook
The global adalimumab market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).
United States Leads the Market
The United States dominates the global adalimumab market due to high biologic therapy adoption, advanced healthcare infrastructure, and increasing autoimmune disease prevalence. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 58.5 million adults in the U.S. are diagnosed with arthritis-related conditions annually, significantly supporting demand for TNF-alpha inhibitor therapies.
The country also maintains strong biosimilar regulatory frameworks through the FDA, encouraging the commercialization of interchangeable adalimumab products. Increasing insurance coverage, specialty pharmacy expansion, and hospital biologics utilization continue to strengthen the U.S. market position. Major pharmaceutical companies are also expanding manufacturing and commercialization partnerships to improve domestic biologics supply capabilities.
China to Record Strong Growth
China is expected to witness strong growth in the adalimumab market due to increasing healthcare investments, expanding biologics manufacturing, and rising autoimmune disease diagnosis rates. According to the National Medical Products Administration (NMPA), China has accelerated biologics and biosimilar approvals to improve treatment accessibility across chronic inflammatory diseases.
The country’s pharmaceutical sector continues to experience significant manufacturing expansion supported by government-led biotechnology development programs. Increasing hospital infrastructure, rising healthcare expenditure, and strong domestic biologics production capabilities are creating favourable conditions for adalimumab adoption.
Chinese biosimilar manufacturers are also expanding exports and regional partnerships across Asia-Pacific markets, strengthening the country’s role in global biologics supply chains.
Competitive Landscape
The global adalimumab market is highly competitive and characterized by strong participation from leading biologics manufacturers and biosimilar developers. Companies are focusing on product differentiation, interchangeable biosimilar approvals, manufacturing expansion, and strategic partnerships to strengthen market positioning.
AbbVie continues to maintain a dominant position through its Humira franchise and lifecycle management strategies. Amgen, Samsung Bioepis, Sandoz (Novartis), and Boehringer Ingelheim are aggressively expanding biosimilar commercialization initiatives across major healthcare markets. Manufacturers are increasingly investing in high-concentration citrate-free formulations, patient affordability programs, and global regulatory approvals to improve competitive advantages in the evolving biologics landscape.
Recent Developments
- In March 2026, Sandoz entered a strategic partnership agreement with Samsung Bioepis for the development and commercialization of up to five biosimilar assets, strengthening their global biosimilars pipeline and expanding competition in the biologics and biosimilars market.
- In May 2025, Celltrion received expanded U.S. FDA interchangeability designation for YUFLYMA (adalimumab-aaty) across all approved dosage forms and strengths, strengthening competition in the adalimumab biosimilars market and supporting broader pharmacy-level substitution of Humira biosimilars.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Adalimumab market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Adalimumab Market Sales Analysis – Product Type | Treatment Stage | End User ($ Million)
- Adalimumab Market Sales Performance of Top Countries
1.1 Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
2.1 Scope of the Study
2.2 Analyst Insight & Current Market Trends
2.2.1 Key Adalimumab Market Trends
2.2.2 Market Recommendations
2.3 Porter's Five Forces Analysis for the Adalimumab Market
2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes
- Market Determinants
3.1 Market Drivers
3.1.1 Drivers For Global Adalimumab Market: Impact Analysis
3.2 Market Pain Points and Challenges
3.2.1 Restraints For Global Adalimumab Market: Impact Analysis
3.3 Market Opportunities
3.3.1 Opportunities For Global Adalimumab Market: Impact Analysis
- Competitive Landscape
4.1 Competitive Dashboard – Adalimumab Market Revenue and Share by Manufacturers
- Adalimumab Product Comparison Analysis
- Top Market Player Ranking Matrix
4.2 Key Company Analysis
4.2.1 AbbVie
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy
4.2.2 Amgen
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy
4.2.3 Samsung Bioepis
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy
4.2.4 Sandoz (Novartis)
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy
4.2.5 Boehringer Ingelheim
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy
4.3 Top Winning Strategies by Market Players
4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration
- Global Adalimumab Market Sales Analysis by Product Type ($ Million)
5.1 Original/Breference Adalimumab
5.2 Biosimilar Adalimumab
- Global Adalimumab Market Sales Analysis by Treatment Stage ($ Million)
6.1 First-line Biologic Therapy
6.2 Second-line Biologic Therapy
6.3 Maintenance Therapy
- Global Adalimumab Market Sales Analysis by End User ($ Million)
7.1 Hospitals
7.2 Specialty Clinics
7.3 Ambulatory Infusion Centers
7.4 Homecare Settings
- Regional Analysis
8.1 North American Adalimumab Market Sales Analysis – Product Type | Treatment Stage | End User | Country ($ Million)
8.1.1 United States
8.1.2 Canada
8.2 European Adalimumab Market Sales Analysis – Product Type | Treatment Stage | End User | Country ($ Million)
8.2.1 UK
8.2.2 Germany
8.2.3 Italy
8.2.4 Spain
8.2.5 France
8.2.6 Russia
8.2.7 Rest of Europe
8.3 Asia-Pacific Adalimumab Market Sales Analysis – Product Type | Treatment Stage | End User | Country ($ Million)
8.3.1 China
8.3.2 Japan
8.3.3 South Korea
8.3.4 India
8.3.5 Australia & New Zealand
8.3.6 ASEAN Countries
8.3.7 Rest of Asia-Pacific
8.4 Rest of the World Adalimumab Market Sales Analysis – Product Type | Treatment Stage | End User | Country ($ Million)
8.4.1 Latin America
8.4.2 Middle East and Africa
- Company Profiles
9.1 AbbVie
9.1.1 Quick Facts
9.1.2 Company Overview
9.1.3 Product Portfolio
9.1.4 Business Strategies
9.2 Amgen
9.2.1 Quick Facts
9.2.2 Company Overview
9.2.3 Product Portfolio
9.2.4 Business Strategies
9.3 Samsung Bioepis
9.3.1 Quick Facts
9.3.2 Company Overview
9.3.3 Product Portfolio
9.3.4 Business Strategies
9.4 Sandoz (Novartis)
9.4.1 Quick Facts
9.4.2 Company Overview
9.4.3 Product Portfolio
9.4.4 Business Strategies
9.5 Boehringer Ingelheim
9.5.1 Quick Facts
9.5.2 Company Overview
9.5.3 Product Portfolio
9.5.4 Business Strategies
9.6 Alvotech
9.6.1 Quick Facts
9.6.2 Company Overview
9.6.3 Product Portfolio
9.6.4 Business Strategies
9.7 Biocon Biologics
9.7.1 Quick Facts
9.7.2 Company Overview
9.7.3 Product Portfolio
9.7.4 Business Strategies
9.8 Bio-Thera Solutions
9.8.1 Quick Facts
9.8.2 Company Overview
9.8.3 Product Portfolio
9.8.4 Business Strategies
9.9 Cadila Pharmaceuticals
9.9.1 Quick Facts
9.9.2 Company Overview
9.9.3 Product Portfolio
9.9.4 Business Strategies
9.10 Celltrion
9.10.1 Quick Facts
9.10.2 Company Overview
9.10.3 Product Portfolio
9.10.4 Business Strategies
9.11 Coherus BioSciences
9.11.1 Quick Facts
9.11.2 Company Overview
9.11.3 Product Portfolio
9.11.4 Business Strategies
9.12 Dr. Reddy’s Laboratories
9.12.1 Quick Facts
9.12.2 Company Overview
9.12.3 Product Portfolio
9.12.4 Business Strategies
9.13 Fresenius Kabi
9.13.1 Quick Facts
9.13.2 Company Overview
9.13.3 Product Portfolio
9.13.4 Business Strategies
9.14 Hisun Pharma
9.14.1 Quick Facts
9.14.2 Company Overview
9.14.3 Product Portfolio
9.14.4 Business Strategies
9.15 Intas Pharmaceuticals (Accord BioPharma)
9.15.1 Quick Facts
9.15.2 Company Overview
9.15.3 Product Portfolio
9.15.4 Business Strategies
9.16 Lupin
9.16.1 Quick Facts
9.16.2 Company Overview
9.16.3 Product Portfolio
9.16.4 Business Strategies
9.17 Mabwell Bioscience
9.17.1 Quick Facts
9.17.2 Company Overview
9.17.3 Product Portfolio
9.17.4 Business Strategies
9.18 Organon
9.18.1 Quick Facts
9.18.2 Company Overview
9.18.3 Product Portfolio
9.18.4 Business Strategies
9.19 Pfizer
9.19.1 Quick Facts
9.19.2 Company Overview
9.19.3 Product Portfolio
9.19.4 Business Strategies
9.20 Reliance Life Sciences
9.20.1 Quick Facts
9.20.2 Company Overview
9.20.3 Product Portfolio
9.20.4 Business Strategies
9.21 Shanghai Henlius Biotech
9.21.1 Quick Facts
9.21.2 Company Overview
9.21.3 Product Portfolio
9.21.4 Business Strategies
9.22 STADA Arzneimittel
9.22.1 Quick Facts
9.22.2 Company Overview
9.22.3 Product Portfolio
9.22.4 Business Strategies
9.23 Torrent Pharmaceuticals
9.23.1 Quick Facts
9.23.2 Company Overview
9.23.3 Product Portfolio
9.23.4 Business Strategies
9.24 Viatris
9.24.1 Quick Facts
9.24.2 Company Overview
9.24.3 Product Portfolio
9.24.4 Business Strategies
9.25 Zydus Lifesciences
9.25.1 Quick Facts
9.25.2 Company Overview
9.25.3 Product Portfolio
9.25.4 Business Strategies
1. Global Adalimumab Market Research and Analysis by Product Type, 2025–2035 ($ Million)
2. Global Original/Breference Adalimumab Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Biosimilar Adalimumab Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Adalimumab Market Research and Analysis by Treatment Stage, 2025–2035 ($ Million)
5. Global First-line Biologic Therapy Adalimumab Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Second-line Biologic Therapy Adalimumab Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Maintenance Therapy Adalimumab Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Adalimumab Market Research and Analysis by End User, 2025–2035 ($ Million)
9. Global Adalimumab for Hospitals Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Adalimumab for Specialty Clinics Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Adalimumab for Ambulatory Infusion Centers Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Adalimumab for Homecare Settings Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Adalimumab Market Research and Analysis by Region, 2025–2035 ($ Million)
14. North America Adalimumab Market Research and Analysis by Country, 2025–2035 ($ Million)
15. North America Adalimumab Market Research and Analysis by Product Type, 2025–2035 ($ Million)
16. North America Adalimumab Market Research and Analysis by Treatment Stage, 2025–2035 ($ Million)
17. North America Adalimumab Market Research and Analysis by End User, 2025–2035 ($ Million)
18. Europe Adalimumab Market Research and Analysis by Country, 2025–2035 ($ Million)
19. Europe Adalimumab Market Research and Analysis by Product Type, 2025–2035 ($ Million)
20. Europe Adalimumab Market Research and Analysis by Treatment Stage, 2025–2035 ($ Million)
21. Europe Adalimumab Market Research and Analysis by End User, 2025–2035 ($ Million)
22. Asia-Pacific Adalimumab Market Research and Analysis by Country, 2025–2035 ($ Million)
23. Asia-Pacific Adalimumab Market Research and Analysis by Product Type, 2025–2035 ($ Million)
24. Asia-Pacific Adalimumab Market Research and Analysis by Treatment Stage, 2025–2035 ($ Million)
25. Asia-Pacific Adalimumab Market Research and Analysis by End User, 2025–2035 ($ Million)
26. Rest of the World Adalimumab Market Research and Analysis by Region, 2025–2035 ($ Million)
27. Rest of the World Adalimumab Market Research and Analysis by Product Type, 2025–2035 ($ Million)
28. Rest of the World Adalimumab Market Research and Analysis by Treatment Stage, 2025–2035 ($ Million)
29. Rest of the World Adalimumab Market Research and Analysis by End User, 2025–2035 ($ Million)
30. Global Adalimumab Market – Top 5 Companies Market Share Analysis, 2025 (%)
31. Global Adalimumab Market – Top 5 Companies Revenue Comparison, 2025–2035 ($ Million)
1. Global Adalimumab Market Share by Product Type, 2025 Vs 2035 (%)
2. Global Original/Breference Adalimumab Market Research and Analysis by Region, 2025 Vs 2035 (%)
3. Global Biosimilar Adalimumab Market Research and Analysis by Region, 2025 Vs 2035 (%)
4. Global Adalimumab Market Share by Treatment Stage, 2025 Vs 2035 (%)
5. Global First-line Biologic Therapy Adalimumab Market Research and Analysis by Region, 2025 Vs 2035 (%)
6. Global Second-line Biologic Therapy Adalimumab Market Research and Analysis by Region, 2025 Vs 2035 (%)
7. Global Maintenance Therapy Adalimumab Market Research and Analysis by Region, 2025 Vs 2035 (%)
8. Global Adalimumab Market Share by End User, 2025 Vs 2035 (%)
9. Global Adalimumab for Hospitals Market Research and Analysis by Region, 2025 Vs 2035 (%)
10. Global Adalimumab for Specialty Clinics Market Research and Analysis by Region, 2025 Vs 2035 (%)
11. Global Adalimumab for Ambulatory Infusion Centers Market Research and Analysis by Region, 2025 Vs 2035 (%)
12. Global Adalimumab for Homecare Settings Market Research and Analysis by Region, 2025 Vs 2035 (%)
13. Global Adalimumab Market Share by Region, 2025 Vs 2035 (%)
14. U.S. Adalimumab Market Size, 2025–2035 ($ Million)
15. Canada Adalimumab Market Size, 2025–2035 ($ Million)
16. UK Adalimumab Market Size, 2025–2035 ($ Million)
17. France Adalimumab Market Size, 2025–2035 ($ Million)
18. Germany Adalimumab Market Size, 2025–2035 ($ Million)
19. Italy Adalimumab Market Size, 2025–2035 ($ Million)
20. Spain Adalimumab Market Size, 2025–2035 ($ Million)
21. Russia Adalimumab Market Size, 2025–2035 ($ Million)
22. India Adalimumab Market Size, 2025–2035 ($ Million)
23. China Adalimumab Market Size, 2025–2035 ($ Million)
24. Japan Adalimumab Market Size, 2025–2035 ($ Million)
25. South Korea Adalimumab Market Size, 2025–2035 ($ Million)
26. Australia & New Zealand Adalimumab Market Size, 2025–2035 ($ Million)
27. ASEAN Adalimumab Market Size, 2025–2035 ($ Million)
28. Rest of Asia-Pacific Adalimumab Market Size, 2025–2035 ($ Million)
29. Latin America Adalimumab Market Size, 2025–2035 ($ Million)
30. Middle East & Africa Adalimumab Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
